Pacific Dental Services and American Diabetes Association partner to increase awareness of the link between oral health and diabetes
Research shows that harmful bacteria and inflammation in the mouth can indicate and even cause systemic conditions throughout the body.IRVINE, Calif., Nov. 18, 2021 /PRNewswire/ -- Leading dental support organization Pacific Dental Services® (PDS) has announced a new partnership with the American Diabetes Association® to increase awareness of the link between periodontal disease and diabetes, and how oral health providers can assist patients in preventing and managing this chronic health condition. The timing of this announcement coincides with American Diabetes Month ™, a month-long ...
Source: Dental Technology Blog - December 2, 2021 Category: Dentistry Source Type: news

Janssen Seeks Approval of IMBRUVICA ®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 30 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new treatment option for IMBRUVICA® (ibrutinib) as a fixed-duration combination with venetoclax (I+V) for adult patients with previously untreated chronic lymphocytic leukaemia (CLL)."Ibrutinib was the first approved Bruton’s tyrosine kinase inhibitor and over the past seven years has become a key treatment for CLL and some other B-cell malignancies, treating more than 250,000 pati...
Source: Johnson and Johnson - November 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Stomach bloating: The taste in your mouth that could indicate a tumour is growing
STOMACH bloating could in actual fact be a lump at the top of the stomach, indicative of cancer. The latest figures show that there are, on average, 6,453 cases of stomach cancer in the UK each year. (Source: Daily Express - Health)
Source: Daily Express - Health - November 26, 2021 Category: Consumer Health News Source Type: news

Too many firefighters are dying of cancer. UCLA ’s Derek Urwin aims to change that
They ’re our modern-day superheroes — charging into burning buildings without hesitation, rescuing those in peril, staving off destruction. Butin risking their lives for us, firefighters pay a heavy price, with cancer rates that far outpace the public at large.Derek Urwin, a longtime firefighter who expects to complete his Ph.D. in chemistry during the winter quarter, is out to change that, using his knowledge of chemistry to  improve firefighter health and safety and, ultimately, bring these cancer rates down. It’s a mission that had a very personal origin.In 2014, Urwin ’s brother Isaac,...
Source: UCLA Newsroom: Health Sciences - November 22, 2021 Category: Universities & Medical Training Source Type: news

Tofacitinib Postmarketing Data Shed Light on JAK Inhibitor Risks Tofacitinib Postmarketing Data Shed Light on JAK Inhibitor Risks
Analyses of the phase 3b/4 ORAL Surveillance trial results found independent factors for risk for major adverse cardiovascular events, cancer, and venous thromboembolic events.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2021 Category: Cardiology Tags: Rheumatology News Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Heartland Dental Supported Practices Give Back to Their Communities
Company Provided Free Dental Care to Over 2,600 Patients across its Supported Offices to DateEFFINGHAM, Ill., Nov. 9, 2021 /PRNewswire/ -- Heartland Dental today announced the progress across their supported practices to give back to the communities they serve and make dental care more accessible. From Free Dentistry Days to special events, the Heartland Dental network continues to make an impact. Free Dentistry Days is an opportunity for supported doctors and team members to provide basic dental care such as cleanings, fillings, and extractions at no cost to the patients. Since 2010, Free Dentistry Days have pro...
Source: Dental Technology Blog - November 17, 2021 Category: Dentistry Source Type: news

Fatty acid found in palm oil linked to spread of cancer
Study on mice found palmitic acid promoted metastasis in mouth and skin cancersScientists have shown how a fatty acid found in palm oil can encourage the spread of cancer, in work that could pave the way for new treatments.The study, on mice, found that palmitic acid promoted metastasis in mouth and skin cancers. In future, this process could be targeted with drugs or carefully designed eating plans, but the team behind the work cautioned against patients putting themselves on diets in the absence of clinical trials.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 10, 2021 Category: Science Authors: Hannah Devlin Science correspondent Tags: Cancer Science Palm oil Health World news Source Type: news

Viome Life Sciences raises $54M for expanded clinical trials
The clinical trial results will be used to expand Viome ’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers. (Source: mobihealthnews)
Source: mobihealthnews - November 10, 2021 Category: Information Technology Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Results With De-escalated Radiotherapy for HPV+ve Oral Cancer Results With De-escalated Radiotherapy for HPV+ve Oral Cancer
De-escalated adjuvant radiation therapy demonstrated less toxicity, improved swallowing function and quality of life, and also was clinically non-inferior to standard of care.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

PET tracer proves effective for assessing immunotherapy
PET imaging can show whether patients with melanoma or non-small cell lung cance...Read more on AuntMinnie.comRelated Reading: U.S. cancer care financial burden hit $21B in 2019 New PET radiotracer more effective at detecting cancer PET tracer predicts response to immunotherapy AI can lend a hand in diagnosis, prognosis of oral SCC PET/CT shows promise predicting outcomes in head, neck cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 3, 2021 Category: Radiology Source Type: news

EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 3, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Takeda Pharmaceutical Limited Company as a specialty pharmacy provider for EXKIVITYTM (mobocertinib) for the treatment of adult patients with locally adv... (Source: McKesson News)
Source: McKesson News - November 3, 2021 Category: Information Technology Source Type: news

Mouth cancer symptoms: The strange 'patches' inside your mouth you should never ignore
MOUTH cancer symptoms can be quite difficult to spot during its early stages, but there are a number of warning signs that you should be looking out for. These are the strange patches inside your mouth that could be an early symptom of mouth cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - November 2, 2021 Category: Consumer Health News Source Type: news

Schools Could Help More Kids Get the COVID-19 Vaccine. But History Has Some Warnings
Now that the U.S. Food and Drug Administration has authorized Pfizer-BioNTech’s vaccine for kids aged 5 to 11, the Biden Administration has signaled that it will rely on a “trusted messenger” to get information to parents and provide access to vaccines once they’re approved by the Centers for Disease Control and Prevention: schools. As part of the plan to deliver COVID-19 vaccines to the youngest population yet, schools will again take on a role they’ve assumed during health crises throughout American history: promoting vaccination to keep kids and communities safe from infectious disease. &ld...
Source: TIME: Health - November 1, 2021 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Schools Could Help More Kids Get the COVID-19 Vaccine. But History Has Some Warnings
Now that the U.S. Food and Drug Administration has authorized Pfizer-BioNTech’s vaccine for kids aged 5 to 11, the Biden Administration has signaled that it will rely on a “trusted messenger” to get information to parents and provide access to vaccines once they’re approved by the Centers for Disease Control and Prevention: schools. As part of the plan to deliver COVID-19 vaccines to the youngest population yet, schools will again take on a role they’ve assumed during health crises throughout American history: promoting vaccination to keep kids and communities safe from infectious disease. &ld...
Source: TIME: Science - November 1, 2021 Category: Science Authors: Tara Law Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Three years backlog! - Lives in danger as NHS dentistry faces 'worst crisis ever'
PEOPLE will die due to missed oral cancer diagnoses as NHS dentistry faces its worst crisis ever, dentists and watchdogs warn. (Source: Daily Express - Health)
Source: Daily Express - Health - October 31, 2021 Category: Consumer Health News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mouth cancer: What to look for and the 60 second check 'that can save your life'
MOUTH cancer is the sixth most common cancer in the world, though it's much less common in the UK. Also known as oral cancer, it can occur when a tumour develops in a part of the mouth. (Source: Daily Express - Health)
Source: Daily Express - Health - October 24, 2021 Category: Consumer Health News Source Type: news

Cancer: The ‘common’ mouth problem increasing the risk of the deadly disease by 50%
CANCER death rates could soon start climbing as a result of the extensive NHS backlog. Researchers have long reiterated that the disease is highly preventable. One sign in the mouth could signal you're at high risk, warranting immediate treatment. (Source: Daily Express - Health)
Source: Daily Express - Health - October 20, 2021 Category: Consumer Health News Source Type: news

Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Galera Therapeutics stock plunged by more than 70% Tuesday after the Malvern biopharmaceutical firm said its lead experimental cancer therapy failed to meet its primary endpoint in late-stage clinical testing. The new drug candidate, called GC4419, is under development as a treatment for severe oral mucositis in patients with locally advanced head and neck cancer undergoing radiotherapy. The trial did not meet its primary endpoint of reduction in the incidence of severe oral mucositis, a condition… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 19, 2021 Category: Biotechnology Authors: John George Source Type: news

Johnson & Johnson Reports Q3 2021 Results
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of ou...
Source: Johnson and Johnson - October 19, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news

Mouth Cancer Action Month
November is Mouth Cancer Action Month, a campaign spearheaded by the Oral Health Foundation and the Mouth Cancer Foundation which aims to save lives by promoting prevention and early detection of oral cancers. (Source: NHS Networks)
Source: NHS Networks - October 13, 2021 Category: UK Health Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque p...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Spending on new oral cancer drugs with no documented OS benefit high in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

Can Cannabis Help Your Gut?
When Joe Silverman developed Crohn’s disease at age 21, the symptoms started out mild. While the sight of blood in his stools initially freaked him out, what really bothered him was the frequent abdominal pain and bloating that occurred as his condition progressed to moderate and then severe. Dietary changes didn’t make a difference, so he began taking prescription oral anti-inflammatory drugs that are often used to treat certain bowel diseases, which alleviated but didn’t eliminate his discomfort. He started using prescription steroid suppositories to cope with flare-ups of the inflammatory bowel disease...
Source: TIME: Health - September 23, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Source Type: news

Theragnostics enters licensing deal with AAA for Ga-68 PET
Theragnostics has signed a global licensing agreement with Advanced Accelerato...Read more on AuntMinnie.comRelated Reading: Theragnostics names two new board directors Theragnostics, German hospital to study THG-008 for PET SBI, Theragnostics ink oral cancer technology deal GE, Theragnostics partner on PSMA agent Theragnostics inks AstraZeneca agreement (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 22, 2021 Category: Radiology Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim data from the randomised phase II coopERA Breast Cancer trial evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in post-menopausal women with ER-positive, HER2-negative early breast cancer. In the window of opportunity phase, after 14 days of treatment, giredestrant showed a reduction in Ki67, a prognostic marker that measures tumour proliferation, compared to anastrozole (80% versus 67% respectively, p=0.0222). The safety ...
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves First Oral Drug for NSCLC With EGFR Exon20 Insertion FDA Approves First Oral Drug for NSCLC With EGFR Exon20 Insertion
The FDA has granted an accelerated approval to mobocertinib for the treatment of locally advanced or metastatic nonsmall cell lung cancer with a specific type of EGFR mutation.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

I Didn ’t Want to Push My Aunt to Get the Vaccine. Now I Live With Regrets
In normal times, the ICU is a dreadful place. Sickness lingers like a fog. You can feel it, sense it, even hear it—the machinery pumping, the alarms ringing, the nurses scrambling. In pandemic times, the ICU is chilling. Death lives here. Medical staff members wear green biohazard suits, face shields, latex gloves and shoe coverings. Strips of red tape—“ISOLATION,” they read—mark the windows and doors of individual rooms. Behind each is a patient who cannot breathe on their own, kept alive by a ventilation machine that is connected to an invasive tube running down their windpipe and into the l...
Source: TIME: Health - September 12, 2021 Category: Consumer Health News Authors: Ross Dellenger Tags: Uncategorized Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Fecal Transplants: a New Treatment for IBD
Linda Ann Sasser has had ulcerative colitis since she was 20, but it wasn’t until May 2019, about 30 years later, that her condition hit a low point: not only did she have a major flare-up of chronic inflammatory bowel disease (IBD), but on top of it, she had Clostridioides difficile (or C. diff), a highly contagious bacterial infection that causes severe diarrhea and inflammation of the colon. “I became really, really sick with bloody diarrhea 30 times a day and chronic stomach pain,” Sasser says. While hospitalized for 12 days, she was given oral steroid medications, which didn’t help, then IV ste...
Source: TIME: Health - September 9, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Disease feature Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

NIDCR's Fall 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   NIDCR News 5 Q&As About “Oral Health in America: Advances and Challenges” NIDCR issued a brief Q&A regarding details of the forthcoming report Oral Health in America: Advances and Challenges, which will be published in Fall 2021. This comprehensive report will examine improvements in oral health over t...
Source: NIDCR Science News - September 1, 2021 Category: Dentistry Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Health chiefs recall batch of diabetes medicine Metformin after cancer-causing chemical find
British pharmacies stocking the affected medicine - an oral solution known as metformin - were told to pull it after finding it contained nitrosodimethylamine. (Source: the Mail online | Health)
Source: the Mail online | Health - August 25, 2021 Category: Consumer Health News Source Type: news

Mesothelioma Olaparib Clinical Trial Targets Genetic Mutation
The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug targeting cancer-driven genetic mutations. This single-center, phase II clinical trial is open to patients with either pleural mesothelioma or peritoneal mesothelioma. Olaparib, also known by the brand name Lynparza, works by repairing or controlling specific gene mutations. It is known as a protein inhibitor and has been approved by the U.S. Food and Drug Administration for use with breast and ovarian cancers. Mesothelioma, a rare malignancy caused by exposu...
Source: Asbestos and Mesothelioma News - August 24, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

AI helps reduce cancer PET imaging time and dose
An artificial intelligence (AI) algorithm that significantly reduces PET imagin...Read more on AuntMinnie.comRelated Reading: AI can lend a hand in diagnosis, prognosis of oral SCC AI can assess sarcopenia on chest and abdominal CT exams Subtle Medical gets CE Mark for SubtlePET 2.0 AI reduces FDG dose on PET imaging Subtle Medical scores FDA OK for AI-based PET software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 24, 2021 Category: Radiology Source Type: news

AI can lend a hand in diagnosis, prognosis of oral SCC
Radiology and pathology artificial intelligence (AI) algorithms can help i...Read more on AuntMinnie.comRelated Reading: PET/CT shows promise predicting outcomes in head, neck cancer FDG-PET/CT may increase survival in SCC patients CT radiomics predicts esophageal cancer outcomes PET radiomics tailor head/neck cancer treatment Later PET/CT follow-up helps for oropharyngeal cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 19, 2021 Category: Radiology Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Coffee protects against liver cancer while alcohol is linked with numerous cancers
Alcohol consumption is a major risk factor for several cancers including head & neck (mouth, pharynx, larynx), oesophageal and bowel cancer - as well as the more widely known links to breast and liver cancer - according to a new study funded by World Cancer Research Fund (WCRF)(1), and published this week in Nature Communications. The study also found increased coffee consumption was associated with a lower risk of developing liver cancer and basal cell carcinoma of the skin. (Source: World Pharma News)
Source: World Pharma News - August 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer
In patients who had a D2 gastrectomy, perioperative administration of the oral fluoropyrimidine derivative S-1 and oxaliplatin yielded better outcomes than adjuvant capecitabine and oxaliplatin in a phase 3 trial.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Trial to test if cannabis-based mouth spray can treat brain tumours
First such study in the world aims to find out if Sativex combined with chemotherapy can help treat glioblastomaCancer charities and the NHS are preparing to investigate whether a cannabis-based mouth spray can treat brain tumours and help patients to live longer.Doctors will give patients across the UK with a recurrent brain tumour called a glioblastoma the drug, which is known as Sativex, alongside a chemotherapy medication – temozolomide – in a clinical trial in an attempt to kill off cancerous cells.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 3, 2021 Category: Science Authors: Denis Campbell Health policy editor Tags: Cancer Cancer research UK news Medical research Health Science Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia
(Ohio State University Wexner Medical Center) The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Can turmeric reduce joint pain during breast cancer treatment?
(University of California - Davis Health) The UC Davis Comprehensive Cancer Center received a $50,000 grant from the Safeway Foundation. The funding will allow researcher Mili Arora to study whether the spice turmeric can provide pain relief for breast cancer patients on oral anti-estrogen drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

New WHO study links moderate alcohol use with higher cancer risk
(Centre for Addiction and Mental Health) A new study from the World Health Organization's (WHO) International Agency for Research on Cancer (IARC), published in the journal Lancet Oncology, has found an association between alcohol and a substantially higher risk of several forms of cancer, including breast, colon, and oral cancers. Increased risk was evident even among light to moderate drinkers (up to two drinks a day), who represented 1 in 7 of all new cancers in 2020 and more than 100,000 cases worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2021 Category: International Medicine & Public Health Source Type: news